Delivery Order SPE2DB20D3101-SPE2DB21FH9B6
- Not listed
- This federal contract award, valued at $1,195.55, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products...
- This federal contract award from the Defense Logistics Agency (DLA) is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, worth up to $1,924.56, is for delivery orders of pharmaceutical and medical products, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other essential medical supplies. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The federal contract award is for a prime vendor pharmaceutical contract with the Defense Logistics Agency (DLA) awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $3,710.00 and is a firm fixed price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., has an Indefinite Delivery Contract (IDC) with...
- This federal contract award, valued at $1,591.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for pharmaceutical branch prime vendor services, covering a range of medical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant...
- This federal contract award, valued at $140,251.02, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the prime vendor pharmaceutical branch in Philadelphia, with a firm fixed price pricing type. The award has no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
- This federal contract award, valued at $1,493.27, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for a Prime Vendor Pharmaceutical Branch in Philadelphia and has an ultimate completion date of November 4, 2020. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. Amerisourcebergen is a subsidiary of the parent company Cencora, Inc., which also does...
- This federal contract award, valued at $54,571.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC enables Amerisourcebergen to efficiently deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,233.36, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Cencora, Inc. (doing business as Amerisourcebergen) worth up to $999,999,999.00. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range...
- This federal contract award, valued at $1,869.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a delivery order, is for pharmaceutical and medical products to support military healthcare programs. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, that serves as the primary vehicle...
- This federal contract award, valued at $1,470.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB21FH9B6Delivery Order
This federal contract award, valued at $1,732.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the Prime Vendor Pharmaceutical Branch-Philadelphia and is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 2/26/21 |